Previous 10 | Next 10 |
SAN DIEGO, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pf ēnex Expression Technology® to develop and improve protein therapies for unmet patient needs. Using the patented Pf ...
SAN DIEGO, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and improve protein therapies for unmet patient needs. Using the patented Pf...
SAN DIEGO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), today announced that Susan Knudson has resigned for personal reasons from her role as Senior Vice President, Chief Financial Officer effective November 13, 2019, but will continue to support the company by provi...
Pfenex, Inc. (PFNX) Q3 2019 Earnings Conference Call November 7, 2019 16:30 ET Company Participants Eef Schimmelpennink - President & CEO Susan Knudson - CFO Conference Call Participants Brandon Folkes - Cantor Fitzgerald & Co. Jason Butler - JMP Securities Andy H...
Image source: The Motley Fool. Pfenex (NYSEMKT: PFNX) Q3 2019 Earnings Call Nov 07, 2019 , 4:30 p.m. ET Operator Continue reading
Pfenex (NYSEMKT: PFNX ): Q3 GAAP EPS of $0.09 beats by $0.02 . More news on: Pfenex Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Received U.S. FDA approval for PF708 to treat osteoporosis and submitted comparative use human factors (HF) study report to FDA; Commercial launch by Alvogen expected upon FDA decision on the therapeutic equivalence rating relative to Forteo® Announced partnership with Arcellx to...
SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that Eef Schimmelpennink, President and Chief Executive Officer, will be presenting at the Jefferies 2019 London Healthcare Conference on Wednesday, November 20 th , taking place at the Waldorf Hi...
Below are the five companies in the Biotechnology industry with the lowest sales per share. Sales per share is a valuable metric in comparing relative value for companies in the same industry. Actinium Pharmaceuticals Inc. ranks lowest with sales per share of $0.00. Following is Pfenex Inc. w...
Bausch Health Companies (NYSE: BHC ) initiated with Outperform rating and $35 (54% upside) price target at Cowen and Company. More news on: Bausch Health Companies Inc., Illumina, Inc., MannKind Corporation, Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Pfenex Inc. (NYSE American: PFNX) at an offer price of $12.00 per share in cash, plus one non-transferable contractua...
NEW YORK, NY / ACCESSWIRE / September 15, 2020 / Juan Monteverde , founder, and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Pfenex Inc. (NYSE American: PFNX ) relating to it...
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultimately s...